Latest Breaking News On - Kindred bio - Page 1 : comparemela.com

Elanco Animal Health (ELAN) Q1 2024 Earnings Call Transcript

Gallant Deepens Its Bench by Adding Dr. Valentine Williams as Senior Vice President of Clinical Development and Regulatory

Furthering its mission to bring regenerative medicine to all pets, animal biotech company Gallant Therapeutics welcomes an industry leader, Dr. Val Williams,.

Elanco Animal Health Inc. (ELAN) Q4 2021 Earnings Call Transcript

ELAN earnings call for the period ending December 31, 2021.

Kindred Bio: Q4 Earnings Snapshot

Kindred Bio: Q4 Earnings Snapshot March 16, 2021 FacebookTwitterEmail BURLINGAME, Calif. (AP) Kindred Biosciences Inc. (KIN) on Tuesday reported a loss of $10.9 million in its fourth quarter. The Burlingame, California-based company said it had a loss of 28 cents per share. The biopharmaceutical company posted revenue of $951,000 in the period. For the year, the company reported that its loss narrowed to $21.8 million, or 55 cents per share. Revenue was reported as $42.2 million. In the final minutes of trading on Tuesday, the company s shares hit $4.94. A year ago, they were trading at $6.01. This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on KIN at https://www.zacks.com/ap/KIN

Kindred Biosciences (NASDAQ:KIN), (ELAN) - Kindred Biosciences Submits Efficacy Data For KIND-030 As Prophylactic Option In US